BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($4.8B)

Data statis (memuat keuangan langsung…)

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

Komposisi segmen dan pelanggan utama

Detail produk

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

Hubungan Rantai Pasok

Mitra

Pfizer Inc.

Comirnaty COVID vaccine co-development

Dampak: Critical — Pfizer is primary commercialization partner

Pesaing

Moderna, Inc.

mRNA vaccines and oncology

Dampak: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

Dampak: Competing in oncology

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok BioNTech SE.

Info Perusahaan

Kantor Pusat

Mainz, Germany

Didirikan

2008

Karyawan

6,000+

Situs Web

biontech.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor